Online inquiry

IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10280MR)

This product GTTS-WQ10280MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets C5 gene. The antibody can be applied in Choroiditis, Age-related macular degeneration (AMD) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001317163.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 727
UniProt ID P01031
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-C5, LFG 316(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ10280MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10808MR IVTScrip™ mRNA-Anti-G, M777-16-3(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M777-16-3
GTTS-WQ11698MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ15003MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ12209MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ10585MR IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY-3127804
GTTS-WQ10601MR IVTScrip™ mRNA-Anti-PDCD1, LY3300054(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA LY3300054
GTTS-WQ6013MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11975MR IVTScrip™ mRNA-Anti-ERBB3&IGF1R, MM-005(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MM-005
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW